摘要
目的探讨康艾注射液对多发性骨髓瘤细胞增殖的抑制作用及其分子机制,为临床应用康艾注射液治疗多发性骨髓瘤提供实验依据。方法开展体外细胞实验,采用MTT法检测康艾注射液对多发性骨髓瘤RPMI8226细胞增殖、凋亡的影响,并采用蛋白质免疫印迹法检测RPMI8226细胞中Bax、Bcl-2蛋白表达水平。结果试验组RPMI8226细胞成活率较对照组、3-MA组明显降低,且细胞凋亡率显著高于对照组、3-MA组,差异有统计学意义(P<0.05)。对照组与3-MA组的细胞成活率、细胞凋亡率比较差异无统计学意义(P>0.05)。试验组RPMI8226细胞的Bcl-2蛋白显著低于对照组、3-MA组,Bax蛋白表达显著高于对照组、3-MA组,差异有统计学意义(P<0.05)。结论康艾注射液可抑制多发性骨髓瘤细胞增殖,并促进其凋亡,这可能是通过下调Bcl-2,上调Bax蛋白表达水平而实现的。
Objective To explore the inhibiting effect of Kangai Injection on the proliferation of multiple myeloma cells and its analysis mechanism,so as to provide experimental basis for the clinical application of Kangai Injection in the treatment of multiple myeloma.Methods We carried out in vitro cell experiments,using the MTT method to detect the effect of Kangai Injection on the proliferation and apoptosis of multiple myeloma RPMI8226 cells,and using Western blotting to detect the protein expression levels of Bax and Bcl-2 in RPMI8226 cells.Results The survival rate of RPMI8226 cells in the experimental group was significantly lower than the control group and 3-mA group,and the apoptosis rate were significantly higher than the control group and 3-mA group,the difference was statistically significant(P<0.05).There were no significant difference in cell survival rate and apoptosis rate between the control group and 3-m A group(P>0.05).The bcl-2 m RNA of RPMI8226 cells in experimental group was significantly lower than control group and 3-m A group,and the Bax m RNA expression was significantly higher than control group and 3-m A group,the difference was statistically significant(P<0.05).Conclusion Kangai Injection can inhibit the proliferation of multiple myeloma cells and promote their apoptosis,which may be achieved by down regulating Bcl-2 and up regulating the expression level of Bax protein.
作者
王栋范
李慧
WANG Dong-Fan;LI Hui(The Third Department of Internal Medicine,Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Guangzhou 510801.China;Department of Hematology,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510120,China)
出处
《中国药物经济学》
2021年第12期81-83,87,共4页
China Journal of Pharmaceutical Economics
